Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Forkhead box protein I3 (FOXI3) is a member of the forkhead box (FOX) family of transcription factors, characterized by a conserved 'forkhead' or 'winged-helix' DNA-binding domain[2][3][1]. FOXI3 is required for the development and differentiation of multiple structures derived from the pharyngeal arches, including hair, ear (otic placode), jaw, teeth, and thymus[1][3][7]. Pathogenic variants in FOXI3 are causative of certain forms of craniofacial microsomia, including microtia, reflecting its essential developmental role[3][4]. FOXI3 functions as a sequence-specific transcriptional regulator and contains both a nuclear localization signal (NLS) and a transactivation domain (TAD), with its activity regulated by phosphorylation and potentially modulated via protein-protein interactions[2][8]. While FOXI3 is not currently a direct therapeutic target (e.g., for drugs), its mutations are important in clinical genetics, especially developmental disorders affecting craniofacial structures[4][3]. There are no known drugs, mechanisms of drug action, or established biomarkers directly associated with FOXI3 at this time.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Forkhead box protein I3 (FOXI3).